Ligand id: 9625

Name: rovazolac

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 86.64
Molecular weight 452.1
XLogP 6.13
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
A Phase 2 clinical trial evaluating ALX-101 as a topical treatment for moderate atopic dermatitis is underway (see NCT03175354).
Mechanism Of Action and Pharmacodynamic Effects
LXR agonists are predicted to promote regeneration of a damaged dermal barrier and/or maintain dermal barrier integrity and/or reduce inflammatory insult to the dermal barrier [2]. They may also have a role to play in treating neurodegenerative diseases [4].